The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction

DSpace/Manakin Repository

The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction

Citable link to this page

. . . . . .

Title: The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction
Author: Brownstein, John Samuel; Sordo, Margarita; Kohane, Isaac Samuel; Mandl, Kenneth David

Note: Order does not necessarily reflect citation order of authors.

Citation: Brownstein, John S., Margarita Sordo, Isaac S. Kohane, and Kenneth D. Mandl. 2007. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE 2(9): e840.
Full Text & Related Files:
Abstract: Background: COX-2 selective inhibitors are associated with myocardial infarction (MI). We sought to determine whether population health monitoring would have revealed the effect of COX-2 inhibitors on population-level patterns of MI. Methodology/Principal Findings: We conducted a retrospective study of inpatients at two Boston hospitals, from January 1997 to March 2006. There was a population-level rise in the rate of MI that reached 52.0 MI-related hospitalizations per 100,000 (a two standard deviation exceedence) in January of 2000, eight months after the introduction of rofecoxib and one year after celecoxib. The exceedence vanished within one month of the withdrawal of rofecoxib. Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P<0.001). For every million prescriptions of rofecoxib and celecoxib, there was a 0.5% increase in MI (95%CI 0.1 to 0.9) explaining 50.3% of the deviance in yearly variation of MI-related hospitalizations. There was a negative association between mean age at MI and volume of prescriptions for celecoxib and rofecoxib (Spearman correlation, −0.67, P<0.05). Conclusions/Significance: The strong relationship between prescribing and outcome time series supports a population-level impact of COX-2 inhibitors on MI incidence. Further, mean age at MI appears to have been lowered by use of these medications. Use of a population monitoring approach as an adjunct to pharmacovigilence methods might have helped confirm the suspected association, providing earlier support for the market withdrawal of rofecoxib.
Published Version: doi:10.1371/journal.pone.0000840
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950690/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4875879

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters